Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double- blind trial

Circulation

Volumn 98, Issue 7, 1998, Pages 678-686

  Dawson, David L ^a,c   Cutler, Bruce S ^b   Meissner, Mark H ^a   Strandness Jr , D Eugene ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

Cilostazol; Claudication; Drugs; Peripheral vascular disease

Indexed keywords

CILOSTAZOL;

ADULT; AGED; ARTERY OCCLUSION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLATULENCE; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREADMILL ERGOMETRY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; WALKING;

EID: 0032544181     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.7.678     Document Type: Article

References (43)

1. Cawthorn SJ, Taylor LM, Porter J. Nonoperative treatment of chronic lower-limb ischemia. Curr Probl Surg. 1991;28:44-55.
2. Bevan EG, Waller PC, Ramsay LE, Pharmacological approaches to the treatment of intermittent claudication. Drugs Aging. 1992;2:125-136.
3. Uchikawa T, Murakami T, Furukawa H. Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus. Arzneimittelforschung. 1992;42:322-324.
4. Kamiya T, Sakaguchi S. Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities. Arzneimittelforschung. 1985;35:1201-1203.
5. Yasuda K, Sakuma M, Tanabe T. Hemodynamic effect of cilostazol on increasing peripheral blood flow in arteriosclerosis obliterans. Arzneimittelforschung. 1985;35:1198-1200.
6. Mishima T. Clinical evaluation of OPC-13013 on chronic arterial occlusive disease: a double-blind study with ticlopidine. Igakuno Ayumi. 1986;139:133-157.
7. Double-blind parallel comparison of cilostazol and placebo in intermittent claudication. Tokushima, Japan: Otsuka Pharmaceutical Co Ltd; 1986. In-house study No. 21-86-101.
8. Double-blind parallel comparison of 300 mg cilostazol and placebo in intermittent claudication. Tokushima, Japan: Otsuka Pharmaceutical Co Ltd; 1986. In-house study No. 21-86-103.
9. Middleton K, Neu E. Twelve weeks double-blind comparison of cilostazol and placebo in patients with intermittent claudication. Tokushima, Japan: Otsuka Pharmaceutical Co Ltd; 1987. In-house study No. 21-87-101.
10. Taylor LM, Porter JM. Proposed design for a double blinded trial to evaluate medications for treatment of intermittent claudication. J Vasc Surg. 1992;15:882-884.
11. Rutherford RB, Flanigan DP, Gupta SK, Johnston KW, Karmody A, Whittemore AD, Baker JD, Ernst CB. Suggested standards for reports dealing with lower extremity ischemia. J Vasc Surg. 1986;4:80-94.
12. Porter JM, Cutler BS, Lee BY, Reich T, Reichle FA, Scogin JT, Strandness DE. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J. 1982;104:66-72.
13. Gillings D, Koch G, Reich T, Stager WJ. Another look at the pentoxifylline efficacy data for intermittent claudication. J Clin Pharmacol. 1987;27:601-609.
14. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung. 1985; 35:1144-1149.
15. Uehara S, Hirayama A. Effects of cilostazol on platelet function. Arzneimittelforschung. 1989;39:1531-1534.
16. Tanaka K, Gotoh F, Fukuuchi Y, Amano T, Uematsu D, Kawamura J, Yamawaki T, Itoh N, Obara K, Muramatsu K. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke. 1989;20:668-673.
17. Ikeda Y, Kikuchi M, Murakami H, Satoh K, Murata M, Watanabe K, Ando Y. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid, and ticlopidine on platelet functions ex vivo: randomized, double-blind cross-over study. Arzneimittelforschung. 1987;37:563-566.
18. Arcan JC, Panak E. Ticlopidine in the treatment of peripheral occlusive arterial disease. Semin Thromb Hemost. 1989;15:167-170.
19. Balsano F, Coccheri S, Libretti A, Nenci GG, Catalano M, Fortunato G, Grasselli S, Violi F, Hellemans H, van Hove P. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J Lab Clin Med. 1989;114:84-91.
20. Giansante C, Calabrese S, Fisicaro M, Fiotti N, Mitri E. Treatment of intermittent claudication with antiplatelet agents. J Intern Med Res. 1990; 18:400-407.
21. Igawa T, Tani T, Chijiwa T, Shiragiku T, Shimidzu S, Kawamura K, Sato S, Unemi F, Kimura Y. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res. 1990;57: 617-623.
22. Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology. 1988;36:313-320.
23. Coffman JD. Vasodilator drugs in peripheral vascular disease. N Engl J Med. 1979;300:713-717.
24. Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985. Br J Clin Pharmacol. 1988;26:569-576.
25. Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Takai H, Nakai T, Miyabo S. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 1992;20:900-906.
26. Takazakura E, Ohsawa K, Hamamatsu K. Effect of cilostazol (Pletaal) on serum lipid levels in diabetic patients: with special emphasis on the effect of increasing serum levels of high density lipoprotein (HDL) cholesterol. Jpn Pharmacol Therapeutics. 1989;17:2769-2773.
27. Azuma S, Yoshida Y, Kasuga M, Aoyama N, Doi K, Amano M, Fukuda T, Yamakazi T, Baba S. Clinical usefulness of cilostazol in patients with complications due to diabetes: with particular reference to the therapeutic effect on paresthesia, peripheral circulation insufficiency, and lipid metabolism disorder. Clinical Report. 1990;24:5451-5457.
28. Sekiguchi M, Morikawa A, Nakajima K, Ito H, Takahashi M, Tobishima M, Makino I. Clinical usefulness of cilostazol (Pletaal) on diabetic neuropathy and serum lipids levels. Jpn Pharmacol Therapeutics. 1991;19: 3273-3277.
29. Noma Y, Hirota M, Shima K. The effects of cilostazol on the serum lipid levels in the diabetic patient: especially the effects in the patients with hyperlipidemia. Clinical Report. 1992;26:109-113.
30. Bollinger A, Frei C. Double blind study of pentoxiphylline against placebo in patients with intermittent claudication. Pharmatherapeutica. 1977;1:557-562.
31. Dettori AG, Pini M, Moratti A, Paolicelli M, Basevi P, Quintavalla R, Manotti C, Di Leece C. Acenocoumarol and pentoxifylline in intermittent claudication: a controlled clinical study: the APIC Study Group. Angiology. 1989;40:237-248.
32. Di Perri T, Guerrini M. Placebo controlled double blind study with pentoxiphylline of walking performance in patients with intermittent claudication. Angiology. 1983;35:366-372.
33. Gallus AS, Gleadow F, DuPont P, Walsh J, Morley AA, Wenzel A, Alderman M, Chivers D. Intermittent claudication: a double-blind crossover trial of pentoxiphylline. Aust NZJ Med. 1985;15:402-409.
34. Reilly DT, Quinton DN, Barrie WW. A controlled trial of pentoxiphylline (Trental 400) in intermittent claudication: clinical, haemostatic and rheologic effects. Aust N Z J Med. 1987;100:445-447.
35. Roekaerts F, Deleers L. Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration. Angiology. 1984;35:396-406.
36. Strano A, Davi G, Avellone G, Novo S, Pinto A. Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxiphylline in patients with occlusive arterial disease of the lower limbs. Angiology. 1984;35:459-466.
37. Tonak J, Knecht H, Groitl H. Treatment of circulatory disturbances with pentoxiphylline: a double blind study with Trental. Pharmatherapeutica. 1983;3(suppl 1):126-135.
38. Radack K, Wyderski RJ. Conservative management of intermittent claudication. Ann Intern Med. 1990;113:135-146.
39. Lindgärde F, Jelnes R, Björkman H, Adielsson G, Kjellstrom T, Palmquist I, Stavenow L. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease: Scandinavian Study Group. Circulation. 1989;80:1549-1556.
40. Green RM, McNamara J. The effects of pentoxiphylline on patients with intermittent claudication. J Vasc Surg. 1988;7:356-362.
41. AbuRahma AF, Woodruff BA. Effects and limitations of pentoxifylline therapy in various stages of peripheral vascular disease of the lower extremity. Am J Surg. 1990;160:266-270.
42. Thomas JH, Swannack CJ, McAnaw M, Klein S, Kinnaman ML. Iliopoulos JI, Hermreck AS, Pierce GE. Determinants of response to pentoxiphylline therapy in patients with intermittent claudication. Am J Surg. 1987;154: 663-665.
43. Berglund B, Eklund B. Reproducibility of treadmill exercise in patients with intermittent claudication. Clin Physiol. 1981;1:252-256.